MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-10-2026
Exagen Accounts Receivables 2011-2026 | XGN
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Exagen
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10.9 M | 7.84 M | 6.55 M | 6.08 M | 9.65 M | 8.91 M | 5.72 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.9 M | 5.72 M | 7.94 M |
Quarterly Accounts Receivables Exagen
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 11.1 M | 14.3 M | 14.7 M | 7.84 M | 9.39 M | 11.7 M | 10.9 M | 6.55 M | 17 M | 16.2 M | 9.3 M | 6.08 M | 10.6 M | 8.72 M | 10.9 M | 9.65 M | 9.21 M | 8.78 M | 8.22 M | 8.91 M | 8.91 M | 8.91 M | 8.91 M | 5.72 M | 5.72 M | 5.72 M | 5.72 M | 5.95 M | 5.95 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 17 M | 5.72 M | 9.37 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.17 B | $ 113.86 | -0.85 % | $ 34.6 B |  USA |
 |
Danaher Corporation
DHR
|
3.91 B | $ 190.59 | -0.8 % | $ 136 B | USA |
 |
DexCom
DXCM
|
1.22 B | $ 63.64 | 0.68 % | $ 24.8 B | USA |
 |
Fulgent Genetics
FLGT
|
69 M | $ 16.32 | -0.61 % | $ 493 M | USA |
 |
Guardant Health
GH
|
138 M | $ 90.59 | 1.04 % | $ 11.4 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.34 B | $ 107.81 | -1.66 % | $ 8.89 B |  Irlanda |
 |
Illumina
ILMN
|
735 M | $ 127.23 | -0.4 % | $ 20.2 B | USA |
 |
CareDx, Inc
CDNA
|
42.6 M | $ 17.63 | -1.07 % | $ 939 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 274.85 | 0.14 % | $ 22.9 B | USA |
 |
Lantheus Holdings
LNTH
|
359 M | $ 75.68 | -0.28 % | $ 5.11 B | USA |
 |
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Medpace Holdings
MEDP
|
402 M | $ 493.63 | -0.48 % | $ 14.2 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 16.99 | 4.23 % | $ 176 M |  China |
 |
Myriad Genetics
MYGN
|
115 M | $ 4.62 | -1.07 % | $ 428 M | USA |
 |
Co-Diagnostics
CODX
|
190 K | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
NeoGenomics
NEO
|
159 M | $ 7.98 | -0.5 % | $ 1.02 B | USA |
 |
Aspira Women's Health
AWH
|
1.21 M | - | -6.19 % | $ 10.5 M | USA |
 |
Neogen Corporation
NEOG
|
153 M | $ 9.93 | 3.82 % | $ 2.15 B | USA |
 |
Natera
NTRA
|
244 M | $ 207.69 | 1.38 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | USA |
 |
National Research Corporation
NRC
|
11.1 M | $ 17.24 | -0.52 % | $ 386 M | USA |
 |
Pacific Biosciences of California
PACB
|
35.4 M | $ 1.4 | -1.76 % | $ 420 M | USA |
 |
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | China |
 |
Precipio
PRPO
|
1.98 M | $ 26.0 | 0.08 % | $ 41.7 M | USA |
 |
Personalis
PSNL
|
8.14 M | $ 6.21 | -5.57 % | $ 368 M | USA |
 |
Charles River Laboratories International
CRL
|
709 M | $ 167.8 | -0.25 % | $ 8.32 B | USA |
 |
Sotera Health Company
SHC
|
139 M | $ 14.86 | -0.1 % | $ 4.22 B | USA |
 |
Castle Biosciences
CSTL
|
51.2 M | $ 24.96 | 0.93 % | $ 693 M | USA |
 |
Soleno Therapeutics
SLNO
|
28.2 M | $ 52.25 | - | $ 2.66 B | USA |
 |
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | USA |
 |
Neuronetics
STIM
|
16.5 M | $ 1.6 | -9.09 % | $ 106 M | USA |
|
Biodesix
BDSX
|
8.6 M | $ 14.71 | -4.21 % | $ 1.91 B | USA |
 |
Thermo Fisher Scientific
TMO
|
8.9 B | $ 483.56 | -0.95 % | $ 182 B | USA |
 |
VolitionRx Limited
VNRX
|
318 K | $ 0.17 | -0.89 % | $ 21.4 M |  Singapore |
 |
Waters Corporation
WAT
|
829 M | $ 301.9 | -0.72 % | $ 18 B | USA |
 |
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B |  Niderland |
 |
Anixa Biosciences
ANIX
|
173 K | $ 2.59 | - | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
731 K | $ 2.08 | -4.13 % | $ 4.78 M | USA |
 |
BioNano Genomics
BNGO
|
5.2 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Interpace Biosciences
IDXG
|
5.65 M | $ 2.02 | 2.54 % | $ 8.94 M | USA |